Skip to main content
Publications
Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Safety of mf59-adjuvanted influenza vaccination in the elderly: results of a comparative study of mf59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol. 2013 Oct;178(7):1139-45.
Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.
Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.
Myers RP, Brogan AJ, Talbird SE, Thompson J, Marcellin P, Jacobson IM, DeMasi R, Menzie AM, Yoshida EM. Efficacy, safety, and cost-effectiveness in Canada of telaprevir combination therapy by baseline fibrosis stage in treatment-naïve patients with chronic genotype 1 hepatitis C virus infection. Presented at the 2013 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; March 2013.